Dr. Reddy’s Laboratories announced the launch of Lamotrigine Extended-Release Tablets, the generic version of GlaxoSmithKline’s Lamictal XR.

RELATED: Neurological Disorders Resource Center

Lamictal XR is an antiepileptic indicated as adjunct in primary generalized tonic-clonic seizures or partial onset seizures with or without secondary generalization in patients ≥13 years of age, and for conversion to monotherapy in patients ≥13 years of age with partial seizures who are receiving treatment with a single antiepileptic drug.

Lamotrigine is thought to inhibit voltage-sensitive sodium channels, stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (eg, glutamate and aspartate).

Lamotrigine Extended-Release Tablets are available in 25mg, 50mg, 100mg, 200mg, and 300mg dosage strengths in 30-count bottles.

For more information call (908) 203-4900 or visit DrReddys.com.